



UNITED STATES PATENT AND TRADEMARK OFFICE

JO
UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/522,510	09/17/2005	Martin Gimmestad	BAFM0001-100	4461
34132	7590	08/13/2007	EXAMINER	
COZEN O'CONNOR, P.C. 1900 MARKET STREET PHILADELPHIA, PA 19103-3508			MEAH, MOHAMMAD Y	
		ART UNIT	PAPER NUMBER	
		1652		
		MAIL DATE	DELIVERY MODE	
		08/13/2007	PAPER	

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Office Action Summary	Application No.	Applicant(s)
	10/522,510	GIMMESTAD ET AL.
	Examiner	Art Unit
	Mohammad Meah	1652

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --
Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) Responsive to communication(s) filed on 5/24/07.
- 2a) This action is FINAL. 2b) This action is non-final.
- 3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) Claim(s) 1-15 and 24-36 is/are pending in the application.
 - 4a) Of the above claim(s) 24-26 is/are withdrawn from consideration.
- 5) Claim(s) _____ is/are allowed.
- 6) Claim(s) 1-15 and 27-36 is/are rejected.
- 7) Claim(s) 2-4, 27, 1 & 33, 2&34, 3&35, 4&36, 5&32, 6&29, 11 &31 is/are objected to.
- 8) Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) The specification is objected to by the Examiner.
- 10) The drawing(s) filed on _____ is/are: a) accepted or b) objected to by the Examiner.

Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).

Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
 - a) All b) Some * c) None of:
 1. Certified copies of the priority documents have been received.
 2. Certified copies of the priority documents have been received in Application No. _____.
 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- 1) Notice of References Cited (PTO-892)
- 2) Notice of Draftsperson's Patent Drawing Review (PTO-948)
- 3) Information Disclosure Statement(s) (PTO/SB/08)
Paper No(s)/Mail Date _____
- 4) Interview Summary (PTO-413)
Paper No(s)/Mail Date. _____
- 5) Notice of Informal Patent Application
- 6) Other: _____

DETAILED ACTION

Claims 1-26 are pending. Claims 1-15 were examined in the previous action. With supplemental amendment of this application, the applicant, on dates on 5/24/07, cancelled claims 16-23 and amended claims 5-15 and added new claims 27-36. Claims 24-26 remain withdrawn. Therefore claims 1-15 and 27-36 will be examined.

Objections

Claims 1 & 33, 2&34, 3&35, 4&36, 5&32, 6&29, 11 &31 objected to under 37 CFR 1.75(c), as being of improper dependent form for failing to further limit the subject matter of a previous claim. Applicant is required to cancel the claims 33, 34, 35, 36, 32, 29 and 31, or amend the claims 1 & 33, 2&34, 3&35, 4&36, 5&32, 6&29, 11 &31 to place the claim(s) in proper dependent form, or rewrite the claim(s) in independent form. Appropriate correction is required.

Claim 1 the recitation "Biologically pure- -" should be "A biologically pure- -"
Appropriate correction is required.

Claims 2-4 the recitations "Biologically pure- -" should be "The biologically pure- -"
Appropriate correction is required.

Claim 27 line 2 " wherein mutant strain comprises mutant gene—" should be "
wherein the mutant strain comprising a mutant gene—" Appropriate correction is required.

Claim Rejections

35 U.S.C 112

USC 112 rejection 2nd paragraph

The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter, which the applicant regards as his invention.

Claims 13, 14, 30 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

Claim 13 is confusing in recitation “—effector genes—”, What is an effector gene.

Claim 14 is unclear in recitation of pm promoter and effector gene XylS as it is unclear what is Pm means and what is the source of XylS gene.

Claim 30 the recitation of “small amounts of O-acetyl groups” makes the claim indefinite as “small amounts” does not have metes and bound.

USC 112 rejection 1st paragraph written description

The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to

Art Unit: 1652

enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

Claims 1-4, 6, 8-9, 11, 13-14, 27-31, 33-36 are rejected under 35 U.S.C. 112, first paragraph, as containing subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention.

These claims are directed to a genus of mutant strain of *P. fluorescens* having alginate production activity wherein one or more alginate biosynthetic pathway genes (such as C-5 epimerase, algG-gene, etc) are mutated by any means. The mutant strain of *P. fluorescens* claimed in the instant claims, produced by mutating one or more alginate biosynthetic pathway genes (such as C-5 epimerase, algG-gene, etc) by any means, is a large variable genus containing many mutant strains from many sources. The specification teaches few mutant strains of *P. fluorescens* (pF201, pf2012,etc recited in claim 5), which do not represent all mutant strains recited in the instant claims. Specification neither teaches the structures of all C-5 epimerase, algG-gene and other alginate biosynthetic pathway genes nor teaches how all *P. fluorescens* strain will be modified. Therefore, one skilled in the art cannot reasonably conclude that the applicant had possession of the claimed invention at the time the instant application was filed. Applicant is referred to the revised guidelines concerning compliance with the written description requirement of U.S.C. 112, first

paragraph, published in the Official Gazette and also available at www.uspto.gov.

Applicants argument against 112 written description rejection, described on their amendment pages 8-9, is considered but not found persuasive because although the specification teaches few mutant strains of *P. flurescens* (pF201, pf2012, these claims encompass the mutant strain of *P. flurescens* , produced by mutating one or more alginate biosynthetic pathway genes (such as C-5 epimerase, algG-gene, etc) by any means ,is a large variable genus. The genus of *P. flurescens* strains recited in the claims is a large variable genus that are diverse having a variety of biosynthetic pathway mutant genes. As such the strain disclosed are not representative of all the structure and/or function of all strain encompassed by the instant claims. Applicant do not teach how all these diverse strain will be modified to have recited function. Given this lack of description of representative species encompassed by the genus of the claim, the specification fails to sufficiently describe the claimed invention in such full, clear, concise, and exact terms that a skilled artisan would recognize that applicants were in possession of the claimed invention.

Claims 1-4, 6, 8-9, 11, 13-14, 27-31, 33-36 are rejected under 35 U.S.C. 112, first paragraph, because the specification, while being enabling for the few mutant strain of *P. flurescens* (pF201, pf2012,etc recited in claim 5) does not reasonably provide enablement for any mutant strain of *P. flurescens*, produced by mutating one or more alginate biosynthetic pathway genes (such as

Art Unit: 1652

C-5 epimerase, algG-gene, etc) by any means. The claims broadly recite any mutant strain of *P. flurescens* produced any means. There are many means of making mutant strain such as mutations of the gene itself, addition of inhibitors, modification of endogenous modulators, mutating, deleting of specific amino acid residues etc., The specification fails to describe how any *P. flurescens* strain expressing from any source can be mutated by any means to produce alginic acid in the recited levels.

Claims 1-4, 6, 8-9, 11, 13-14, 27-31, 33-36 are so broad as to include many mutant strains of *P. flurescens*, produced by mutating one or more alginic biosynthetic pathway genes (such as C-5 epimerase, algG-gene, etc) by any means. The scope of the claims is not commensurate with the enablement provided by the disclosure with regard to the extremely large number of ways of mutating one or more alginic biosynthetic pathway genes to provide mutant strains of *P. flurescens*. Since the amino acid sequence of a protein determines its structural and functional properties, predictability of which changes can be tolerated in a protein's amino acid sequence and obtain the desired activity requires a knowledge of and guidance with regard to which amino acids in the protein's sequence, if any, are tolerant of modification and which are conserved (i.e. expectedly intolerant to modification), and detailed knowledge of the ways in which the proteins' structure relates to its function. However, in this case the disclosure is limited to a few specific recombinant strains of *P. flurescens* having specific disclosed mutations of particular genes of the alginic biosynthetic pathway.

While recombinant and mutagenesis techniques are known, it is not routine in the art to screen for multiple substitutions or multiple modifications, as encompassed by the instant claims, and the positions within a protein's sequence where amino acid modifications can be made with a reasonable expectation of success in obtaining the desired activity/utility are limited in any protein and the result of such modifications is unpredictable. In addition, one skilled in the art would expect any tolerance to modification for a given protein to diminish with each further and additional modification, e.g. multiple substitutions. Furthermore, there are many means of controlling gene function such as mutations of the gene itself, addition of inhibitors, modification of endogenous modulators, mutating individual nucleic acid, etc. It is not routine in the art to control a gene by any means to obtain desired outcome. Without knowing the structural feature of the protein it encodes, controlling the gene by any means (i.e., such as modification of the gene by mutations) to obtain desired function is unpredictable.

Biosynthesis of aligate involves a large number of different enzymes. Controlling one gene without affecting other genes that involve in the aligate synthesis is difficult. The specification does not support the broad scope of the claims which encompass mutant strains of *P. fluorescens*, produced by mutating one or more alginate biosynthetic pathway genes (such as C-5 epimerase, algG gene, etc) by any means because the specification does not establish: (A) regions of the DNA structure of algG gene which should be modified to control aligate synthesis activity and/or how to control by any means the algG gene or any gene involved in aligate synthesis to obtain desired function without

effecting other genes that involve in the aligate synthesis ; (B) the general tolerance of algG gene or other aligate bio-synthetic genes to modification and extent of such tolerance towards controlling the gene with any means; (C) a rational and predictable scheme for modifying any algG residues or residues of other genes with an expectation of obtaining the desired biological function; and / or controlling the gene by any means towards such biological function (D) the specification provides insufficient guidance as to which of the essentially infinite possible choices is likely to be successful.

Thus, applicants have not provided sufficient guidance to enable one of ordinary skill in the art to make and use the claimed invention in a manner reasonably correlated with the scope of the claims broadly including any mutant strains of *P. flurescens*, produced by mutating one or more aligate biosynthetic pathway genes by any means. The scope of the claims must bear a reasonable correlation with the scope of enablement (In re Fisher, 166 USPQ 19 24 (CCPA 1970)). Without sufficient guidance, making mutant strains of *P. flurescens*, by mutating one or more aligate biosynthetic pathway genes by any means is unpredictable and the experimentation left to those skilled in the art is unnecessarily, and improperly, extensive and undue. See In re Wands 858 F.2d 731, 8 USPQ2nd 1400 (Fed. Cir, 1988).

Applicants argument against 112 enablement rejection, described on their amendment pages 2-3, is considered but not found persuasive because although specification is **enabled** for a few *P. flurescens* strains (PF201, Pf2012 and

Art Unit: 1652

other as recited in claim 5) does not reasonably provide enablement for any *P. fluorescens* strain having mutation of one or more alginate biosynthetic pathway genes by any means as discussed previously.

Applicants argue that the rejection under 35 U.S.C. §112, first paragraph is not proper because applicant's *P. fluorescens* strains described in the instant claims comprise a genus of *P. fluorescens* strain having mutation of one or more alginate biosynthetic pathway genes by any means. These are not persuasive because these claims encompass *P. fluorescens* strain having mutation of any number of alginate biosynthetic pathway genes and mutated by any means.

There are many ways to obtain *P. fluorescens* strain *lacking* one ore more alginate biosynthetic pathway genes such as mutations of the entire gene itself, addition of inhibitors, modification of endogenous modulators, modifying other genes involve in the biosynthetic pathway of alginate, etc., many of which require substantially more information than given in specification. Given this lack of description of the means of mutating alginate biosynthetic pathway genes in any *P. fluorescens* encompassed by the genus of the claims, a skilled artisan is not enabled for finding which of enormous number of way as claimed by applicants to mutate any *P. fluorescens* strain. Without such guidance one of ordinary skill would be reduced to the necessity of producing and testing all of the virtually infinite possibilities. This would clearly constitute **undue** experimentation. While enablement is not precluded by the necessity for routine screening, if a large amount of screening is required, the specification must provide a reasonable amount of guidance with respect to the direction in which the experimentation

Art Unit: 1652

should proceed. Such guidance has **not** been provided in the instant specification.

CLAIM Rejection - 35 U.S.C 102

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless –

- (a) the invention was known or used by others in this country, or patented or described in a printed publication in this or a foreign country, before the invention thereof by the applicant for a patent.
- (b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.
- (e) the invention was described in (1) an application for patent, published under section 122(b), by another filed in the United States before the invention by the applicant for patent or (2) a patent granted on an application for patent by another filed in the United States before the invention by the applicant for patent, except that an international application filed under the treaty defined in section 351(a) shall have the effects for purposes of this subsection of an application filed in the United States only if the international application designated the United States and was published under Article 21(2) of such treaty in the English language.

Claims 1-4, 33-36 are rejected under 35 U.S.C. 102(e) as being anticipated by Huisman et al. (US 2004/0014197) as explained by the previous office action.

Huisman et al. teach mutant strain of *P. fluorescens* producing various polyhydroxy compounds including alginates (upto 80 g/L) wherein *P. fluorescens*

strain further is integrated with nuclease gene. Applicant's argument, that Huisman et al., does not teach *P. fluorescens* or rather any bacterial strain that produce 10g/L alginates is not found to be persuasive because on the contrary Huisman et al teach (see claims 1, 7, 2-3,5) various bacterial strains including *P. fluorescens* wherein 40% dry cell wt is the products (alginates is one of them) and wherein fermentation process using said strain produce 50g/L cell.

THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the date of this final action.


Art Unit: 1652

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Mohammad Meah whose telephone number is 571-272-1261. The examiner can normally be reached on 8:30-5PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Ponnathapu Achutamurthy can be reached on 571-272-0928. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Mohammad Younus Meah, PhD
Examiner, Art Unit 1652
Recombinant Enzymes, 3C31 Remsen Bld
400 Dulany Street, Alexandria, VA 22314
Telephone: 517-272-1261



MOHAMMAD YOUNUS MEAH
PRIMARY EXAMINER
GROUP 1600
1600